FI953180A - Sokeritaudin komplikaatioiden hoitamiseen tarkoitetut koostumukset - Google Patents

Sokeritaudin komplikaatioiden hoitamiseen tarkoitetut koostumukset Download PDF

Info

Publication number
FI953180A
FI953180A FI953180A FI953180A FI953180A FI 953180 A FI953180 A FI 953180A FI 953180 A FI953180 A FI 953180A FI 953180 A FI953180 A FI 953180A FI 953180 A FI953180 A FI 953180A
Authority
FI
Finland
Prior art keywords
compositions
treatment
diabetic complications
diabetic
complications
Prior art date
Application number
FI953180A
Other languages
English (en)
Swedish (sv)
Other versions
FI953180A0 (fi
Inventor
David Frederick Horrobin
Mary Cotter
Norman Cameron
Original Assignee
Scotia Holdings Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9412925A external-priority patent/GB9412925D0/en
Priority claimed from GB9422338A external-priority patent/GB9422338D0/en
Application filed by Scotia Holdings Plc filed Critical Scotia Holdings Plc
Publication of FI953180A0 publication Critical patent/FI953180A0/fi
Priority to TW84109228A priority Critical patent/TW422694B/zh
Publication of FI953180A publication Critical patent/FI953180A/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FI953180A 1994-06-28 1995-06-27 Sokeritaudin komplikaatioiden hoitamiseen tarkoitetut koostumukset FI953180A (fi)

Priority Applications (1)

Application Number Priority Date Filing Date Title
TW84109228A TW422694B (en) 1995-06-16 1995-09-04 Compositions for treatment of diabetic complications

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9412925A GB9412925D0 (en) 1994-06-28 1994-06-28 Combination of aldose reductase inhibitors with gamma-linolenic (GLA) dihomogammalinolenic (DGLA) or arachidonic (AA) acids in the treatment of diabetic
GB9422338A GB9422338D0 (en) 1994-11-04 1994-11-04 Aldose reductase

Publications (2)

Publication Number Publication Date
FI953180A0 FI953180A0 (fi) 1995-06-27
FI953180A true FI953180A (fi) 1995-12-29

Family

ID=26305147

Family Applications (1)

Application Number Title Priority Date Filing Date
FI953180A FI953180A (fi) 1994-06-28 1995-06-27 Sokeritaudin komplikaatioiden hoitamiseen tarkoitetut koostumukset

Country Status (10)

Country Link
US (1) US6069168A (fi)
EP (1) EP0694302A1 (fi)
JP (1) JPH08169823A (fi)
KR (1) KR960000219A (fi)
CN (1) CN1124138A (fi)
AU (1) AU711482B2 (fi)
CA (1) CA2152321A1 (fi)
FI (1) FI953180A (fi)
NO (1) NO952573L (fi)
NZ (1) NZ272428A (fi)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9403855D0 (en) * 1994-03-01 1994-04-20 Scotia Holdings Plc Fatty acid derivatives
GB9714274D0 (en) * 1997-07-08 1997-09-10 Zeneca Ltd Pharmaceutical composition
GB9901809D0 (en) * 1999-01-27 1999-03-17 Scarista Limited Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
US6555573B2 (en) * 2000-12-21 2003-04-29 The Quigley Corporation Method and composition for the topical treatment of diabetic neuropathy
US6864242B2 (en) * 2001-03-05 2005-03-08 Stephen P. Ernest Enteral formulation
US20030118536A1 (en) * 2001-11-06 2003-06-26 Rosenbloom Richard A. Topical compositions and methods for treatment of adverse effects of ionizing radiation
US7435725B2 (en) * 2001-11-06 2008-10-14 The Quigly Corporation Oral compositions and methods for prevention, reduction and treatment of radiation injury
US20030105027A1 (en) * 2001-11-06 2003-06-05 Rosenbloom Richard A. Nutritional supplements and methods for prevention, reduction and treatment of radiation injury
FR2842422B1 (fr) 2002-07-16 2006-06-30 Univ Aix Marseille Ii Compositions destinees au traitement des neuropathies peripheriques, preparation et utilisations
EP2384750A1 (en) * 2002-09-27 2011-11-09 Martek Biosciences Corporation Improved Glycemic Control for Prediabetes and/or Diabetes Type II using Docohexaenoic Acid
US7083813B2 (en) * 2002-11-06 2006-08-01 The Quigley Corporation Methods for the treatment of peripheral neural and vascular ailments
JP4153330B2 (ja) 2003-02-28 2008-09-24 サントリー株式会社 高度不飽和脂肪酸のアスコルビン酸エステル化合物の粉末組成物の製造法およびそれらの組成物
JP2006056795A (ja) * 2004-08-18 2006-03-02 Suntory Ltd ６−ｏ−ｐｕｆａアスコルビン酸エステルを含有する皮膚化粧料並びに飲食品
EP1939192A1 (en) * 2006-12-28 2008-07-02 Neuropharma S.A. Cyclopentanone derivatives, method of synthesis and uses thereof
US20090018151A1 (en) * 2007-02-23 2009-01-15 Ezekiel Fink Topical Treatment of Peripheral diabetic complications
WO2010028067A1 (en) 2008-09-02 2010-03-11 Amarin Corporation Plc Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same
EP3865128A1 (en) 2009-02-10 2021-08-18 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
GB0907413D0 (en) 2009-04-29 2009-06-10 Equateq Ltd Novel methods
CN104042617A (zh) 2009-04-29 2014-09-17 阿马里纳药物爱尔兰有限公司 含有epa和心血管剂的药物组合物以及使用其的方法
CN104856985B (zh) 2009-04-29 2019-01-04 阿马里纳制药爱尔兰有限公司 稳定的药物组合物和使用其的方法
KR20120016677A (ko) 2009-06-15 2012-02-24 아마린 파마, 인크. 병용 스타틴 요법을 받는 대상체에서 ｌｄｌ－ｃ 수준을 상승시키지 않으면서 트리글리세리드를 저하시키기 위한 조성물 및 방법
KR101798670B1 (ko) 2009-09-23 2017-11-16 아마린 코포레이션 피엘씨 오메가-3 지방산 및 스타틴의 히드록시-유도체를 포함하는 제약 조성물 및 그의 사용 방법
KR101115283B1 (ko) 2009-10-15 2012-03-13 대상 주식회사 오메가-3 불포화 지방산과 아스코르빈산과의 복합체의 제조방법
ES2750365T3 (es) * 2010-03-04 2020-03-25 Amarin Pharmaceuticals Ie Ltd Composición para el tratamiento y/o la prevención de enfermedades cardiovasculares
NZ611606A (en) 2010-11-29 2015-10-30 Amarin Pharmaceuticals Ie Ltd Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US8293790B2 (en) 2011-10-19 2012-10-23 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
WO2013070735A1 (en) 2011-11-07 2013-05-16 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
JP6307442B2 (ja) 2012-01-06 2018-04-04 アマリン ファーマシューティカルス アイルランド リミテッド 対象の高感度（ｈｓ−ｃｒｐ）のレベルを低下させる組成物および方法
DK3363433T3 (da) 2012-06-29 2021-03-08 Amarin Pharmaceuticals Ie Ltd Fremgangsmåder til reduktion af risikoen for en kardiovaskulær begivenhed i et individ i statinbehandling ved anvendelse af eicosapentaensyreetylester
US20150265566A1 (en) 2012-11-06 2015-09-24 Amarin Pharmaceuticals Ireland Limited Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy
US9814733B2 (en) 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
WO2015195662A1 (en) 2014-06-16 2015-12-23 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
TW201900160A (zh) 2017-05-19 2019-01-01 愛爾蘭商艾瑪琳製藥愛爾蘭有限公司 用於降低腎功能下降之個體中的三酸甘油酯之組合物及方法
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
MA51765A (fr) 2018-09-24 2020-12-16 Amarin Pharmaceuticals Ie Ltd Procédés de réduction du risque d'événements cardiovasculaires chez un sujet
KR20240012390A (ko) 2021-04-21 2024-01-29 애머린 파마슈티칼스 아일랜드 리미티드 심부전의 위험을 감소시키는 방법

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE49783B1 (en) * 1979-05-18 1985-12-11 Efamol Ltd Pharmaceutical and dietary composition comprising epsilon-linolenic acids
GB8302708D0 (en) * 1983-02-01 1983-03-02 Efamol Ltd Pharmaceutical and dietary composition
GB8326130D0 (en) * 1983-09-29 1983-11-02 Efamol Ltd Topical preparations containing tars and fatty acids
AU4595985A (en) * 1984-08-10 1986-02-13 Sentrachem Limited Cancer treatment
GB8506027D0 (en) * 1985-03-08 1985-04-11 Efamol Ltd Pharmaceutical & dietary compositions
GB8507058D0 (en) * 1985-03-19 1985-04-24 Efamol Ltd Pharmaceutical & dietary compositions
GB8524275D0 (en) * 1985-10-02 1985-11-06 Efamol Ltd Pharmaceutical & dietary compositions
GB8524276D0 (en) * 1985-10-02 1985-11-06 Efamol Ltd Pharmaceutical & dietary compositions
JPS6379834A (ja) * 1986-09-25 1988-04-09 Kozo Niwa 活性酸素抑制組成物
SE8604117D0 (sv) * 1986-09-29 1986-09-29 Kabivitrum Ab Composition
GB8705459D0 (en) * 1987-03-09 1987-04-15 Efamol Ltd Treatment of peptic ulcers
EP0309086A1 (en) * 1987-09-07 1989-03-29 Efamol Holdings Plc Treatment of male pattern baldness and of unwanted hair growth
GB8806737D0 (en) * 1988-03-22 1988-04-20 Efamol Holdings Therapeutic composition & method
GB8813766D0 (en) * 1988-06-10 1988-07-13 Efamol Holdings Essential fatty acid compositions
FR2634779B1 (fr) * 1988-07-29 1994-05-27 Oreal Nouveau systeme anti-oxydant a base d'un ester d'ascorbyle stabilise, contenant, en association au moins un tocopherol ou un melange de tocopherols ou de l'acide cafeique ou un de ses derives, au moins un agent complexant et au moins un polypeptide non thiole, et compositions contenant un tel systeme anti-oxydant
IE63225B1 (en) * 1988-09-13 1995-04-05 Efamol Holdings Use of fatty acids in the treatment of myalgic encephalomyelitis
GB8916734D0 (en) * 1989-07-21 1989-09-06 Efamol Holdings Pharmaceutical and dietary uses of fatty acids
GB8920228D0 (en) * 1989-09-07 1989-10-18 Efamol Holdings Fatty acid therapy
US5078989A (en) * 1990-03-28 1992-01-07 Sunstar K.K. Skin whitening cosmetics
US5278189A (en) * 1990-06-04 1994-01-11 Rath Matthias W Prevention and treatment of occlusive cardiovascular disease with ascorbate and substances that inhibit the binding of lipoprotein (A)

Also Published As

Publication number Publication date
CA2152321A1 (en) 1995-12-29
EP0694302A1 (en) 1996-01-31
NO952573D0 (no) 1995-06-27
NZ272428A (en) 1997-07-27
FI953180A0 (fi) 1995-06-27
AU2176395A (en) 1996-01-11
AU711482B2 (en) 1999-10-14
KR960000219A (ko) 1996-01-25
CN1124138A (zh) 1996-06-12
US6069168A (en) 2000-05-30
JPH08169823A (ja) 1996-07-02
NO952573L (no) 1995-12-29

Similar Documents

Publication Publication Date Title
FI953180A (fi) Sokeritaudin komplikaatioiden hoitamiseen tarkoitetut koostumukset
AU3201095A (en) Substituted thiazoles for the treatment of inflammation
FI971969A (fi) Peräpukamien hoitoon tarkoitettuja koostumuksia ja käyttömenetelmä
FI931657A0 (fi) Menetelmä endo-osteaalisten materiaalien käsittelemiseksi
FI20090217A (fi) Menetelmä elintarvikekoostumuksen valmistamiseksi
NO976063D0 (no) Fremgangsmåte for behandling av diabetes
AU3548795A (en) Benzopyranopyrazolyl derivatives for the treatment of inflammation
DE69513916D1 (de) Oberflächenbehandlungszusammensetzung
FI972584A (fi) Substituoituja atsetidin-2-oneja ateroskleroosin hoitamiseksi
NO990225D0 (no) Medikamenter for behandling av hyperfosfatemi
NO963785D0 (no) Fremgangsmåte for behandling av 5HT2B-reseptor-relaterte betingelser
FI962370A (fi) Laite tissuen valmistamiseksi
FI954119A0 (fi) Menetelmä kiinteän jätteen käsittelemiseksi
AU2424895A (en) Substituted spirodienes for the treatment of inflammation
DE69622461D1 (de) Oberflächenbehandlungszusammensetzung
AU3899893A (en) Compositions for the treatment of acute or chronic inflammation
FI972065A (fi) Menetelmä N-fosfonometyyliglysiinin valmistamiseksi
FI962976A0 (fi) Viherkaihin hoitoon tarkoitettuja koostumuksia, jotka sisältävät beta-salpaajaa
FI942102A0 (fi) Menetelmä alumiinioksaanien valmistamiseksi
FI964229A (fi) Menetelmä doksorubisiinin valmistamiseksi
FI940511A (fi) Menetelmä ferrisulfaatin valmistamiseksi
FI956058A (fi) Menetelmä glutaaridialdehydin valmistamiseksi
FI951759A (fi) Menetelmä 2,2-difluoriketeenisilyyli-O,S-asetaalien ja alfa, alfa-difluori-beta-silyylioksi-1,3-dioksolaani-4-propaanihapon O,S-estereiden valmistamiseksi
FI980091A0 (fi) Menetelmä ylijäämäaktiivilietteen käsittelemiseksi
NO982562D0 (no) Sammensetning for behandling av smerte